Market Overview

Bernstein Says Generic Copaxone Win Could Help Momenta Break through $20 Level

Related MNTA
Momenta Pharmaceuticals Announces Acceptance Of A Clinical Trial Application In Europe for M923, A Biosimilar Version Of Humira
Stocks Hitting 52-Week Lows
Related TEVA
UPDATE: Sterne Agee Upgrades Teva Pharmaceutical
Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic Competition
Sofinnova Ventures Closes $500M Fund (Fox Business)

Momenta Pharmaceuticals (NASDAQ: MNTA) shares spiked sharply Friday following news of a legal ruling invalidating Teva Pharmaceutical's (NYSE: TEVA) patents on Copaxone in 2015 and partly invalidating its 2014 patents.

Bernstein analyst Ronny Gal sees a 75 percent chance of the court decision being favorable for Momenta. The ruling could open the door to Momenta introducing a generic Copaxone within the next few months, according to Gal.

If Momenta is able to introduce the first generic Copaxone by May 2014, Gal believes shares could be valued at $30. This is nearly twice the $15.35 level shares were trading at prior to Friday's spike.

Gal believes a later release by Q4 2015 could spell upside of 30 percent from current levels to $23 per share.

Gal rates Momenta at Outperform with a $20 price target.

Latest Ratings for MNTA

DateFirmActionFromTo
Jun 2014Goldman SachsInitiates Coverage onBuy
May 2014Maxim GroupInitiates Coverage onBuy
May 2014Bank of AmericaUpgradesUnderperformBuy

View More Analyst Ratings for MNTA
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Legal Analyst Ratings Movers

 

Related Articles (MNTA + TEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters